Mukundam Veerabathini, MD
Child & Adolescent Psychiatry · State College, PANPI 1306981964
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 496 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 496 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$1K
- Neurocrine Biosciences, Inc.$802
- Alkermes, Inc.$740
- Johnson & Johnson$541
- plus $2K from 10 others
What the payments were for
- Food & beverage$8,17999%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 78 | $1,643 |
| Otsuka America Pharmaceutical, Inc. | 64 | $1,372 |
| AbbVie(2 entities) | 108 | $1,181 |
| Neurocrine Biosciences, Inc. | 66 | $802 |
| Alkermes, Inc. | 36 | $740 |
| Johnson & Johnson | 33 | $541 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $435 |
| Teva Pharmaceuticals USA, Inc. | 25 | $430 |
| Sunovion Pharmaceuticals Inc. | 18 | $291 |
| Lundbeck LLC | 15 | $280 |
| Axsome Therapeutics, Inc. | 8 | $197 |
| Shire North American Group Inc | 8 | $117 |
| E.r. Squibb & Sons, L.L.C. | 4 | $96 |
| Corium, LLC | 7 | $79 |
| Ironshore Pharmaceuticals Inc. | 2 | $32 |
| Neos Therapeutics, LP | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$250
- ABILIFY ASIMTUFII$228
- ABILIFY MAINTENA$228
How this compares
$8,251 in reported general payments places this provider in the 90th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.
See all child & adolescent psychiatry providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $73,099 |
| RexultiBrexpiprazole | 17 | $24,368 |
| CaplytaLumateperone Tosylate | 11 | $16,842 |
| TrintellixVortioxetine Hydrobromide | 19 | $12,627 |
| Lurasidone Hcl | 26 | $4,724 |
| Chlorpromazine Hcl | 12 | $1,523 |
| Aripiprazole | 28 | $855 |
| Duloxetine Hcl | 92 | $830 |
| Lamotrigine | 73 | $684 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $655 |
| Sertraline Hcl | 83 | $628 |
| Hydroxyzine Hcl | 75 | $613 |
| Trazodone Hcl | 92 | $464 |
| Lorazepam | 80 | $447 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 47 | $413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $802 | $73,09911 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,372 | $24,36817 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,643 | $16,84211 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $435 | $12,62719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.
Other child & adolescent psychiatry in State College
- Craig FeasterState College$18K
- Dennis BorczonErie$120K
- Suzanne LucotCranberry Township$72K
- Dan UdreaWexford$51K
- Robert WilsonErie$34K
- Thomas WindPhiladelphia$17K
- Laura AdangPhiladelphia$15K
- Christoph LamPhiladelphia$13K
- Raman BawejaHershey$11K
- Jeffrey HermannYork$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.